1. Teva Pharmaceuticals Industries Limited (NYSE:TEVA)
Price Target Upside: 44.39%
Teva Pharmaceuticals Industries Limited (NYSE:TEVA) is a global leader in developing, manufacturing, and distributing generic drugs, with a portfolio of over 3,500 products across various therapeutic areas.
In June 2024, Teva Pharmaceuticals Industries Limited (NYSE:TEVA) launched the first-ever authorized generic version of Victoza (liraglutide) injection in the U.S., marking a major milestone as the first generic GLP-1 product available for patients with type 2 diabetes. This move is expected to improve the accessibility and affordability of diabetes treatment. Liraglutide, sold as Saxenda for weight management, opens a potential pathway for weight loss solutions, and Teva Pharmaceuticals Industries Limited (NYSE:TEVA) has expressed plans to launch a generic version of Saxenda in the future.
The company is also exploring other medications that could impact weight management. While not directly focused on weight loss, its research into Ajovy (fremanezumab) for migraines has shown effectiveness in reducing attacks in patients with obesity, addressing a common comorbidity. Additionally, the development of TEV-749 (olanzapine) for schizophrenia reflects Teva Pharmaceuticals Industries Limited (NYSE:TEVA)’s broader commitment to addressing conditions that can influence weight.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced $16.5 billion in revenue for the fourth quarter of 2024, a 9% year-over-year gain. Adjusted EBITDA also increased by 9%, and non-GAAP EPS increased by 10%. This expansion included all business areas, including APIs, generics, and new products. Strong revenue performance combined with efficient expense control is reflected in the total profitability improvement.
Overall, TEVA ranks first among the 10 best weight loss drugs to buy according to analysts. While we acknowledge the potential of TEVA, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than TEVA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
